SIDEWINDER THERAPEUTICS
Live / Applied — Second extension granted (statement of use) (as of 02 Apr 2026)
What this means for you
Not registered yet, but its 11 Dec 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98307987
- Mark type
- Stylized text
- Filed
- 11 Dec 2023
- Published for opposition
- 11 Feb 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for the treatment and prevention of diseases in humans, namely, cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, acute respiratory disease, and rare autoimmune, viral and infectious diseases; pharmaceutical preparations, namely, a drug formulation for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, oncology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation for use in pediatrics, geriatrics, emergency psychiatry, family psychiatry, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases; pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, and the integumentary system; pharmaceutical preparations for the treatment or prevention of muscle loss, metabolic conditions and diseases, gastrointestinal conditions and diseases, neurological conditions and diseases, cancer, osteoporosis, inflammatory conditions and diseases, genetic conditions and diseases, muscle diseases and disorders, hepatic conditions and diseases, fibrosis, malnutrition, atrophic diseases and conditions, epilepsy, sarcopenia, myopathies, neuropathies, neurodegenerative diseases, traumatic brain injury, concussions, movement disorders, dystrophies, anemias, and orphan diseases; pharmaceutical and biological preparations, namely, precision therapeutics for the treatment or prevention of diseases, disorders and conditions associated with the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, and the integumentary system; pharmaceutical and biological preparations, namely, large molecule precision therapeutics for the treatment or prevention of diseases, disorders and conditions associated with the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, and the integumentary system
Owner
- Sidewinder Therapeutics, Inc., San Diego, CA, US
- Sidewinder Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 02 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Apr 2026 — SOU EXTENSION 2 GRANTED
- 01 Apr 2026 — SOU EXTENSION 2 FILED
- 01 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 25 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Apr 2025 — SOU EXTENSION 1 GRANTED
- 24 Apr 2025 — SOU EXTENSION 1 FILED
- 24 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Feb 2025 — PUBLISHED FOR OPPOSITION
- 05 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE